Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Reports Robust Q2 FY27 With PAT Surging 450% YoY

Balaxi Pharmaceuticals delivered strong consolidated Q2 FY27 results, with revenue from operations rising 44.85% YoY to ₹8,137.23 lakh and total income

Balaxi Pharmaceuticals Reports Robust Q2 FY27 With PAT Surging 450% YoY

Balaxi Pharmaceuticals Ltd · Investor Presentation · 16 Nov 2026, 6:06 pm

Balaxi Pharmaceuticals Reports Robust Q2 FY27 With PAT Surging 450% YoY Balaxi Pharmaceuticals delivered strong consolidated Q2 FY27 results, with revenue from operations rising 44.85% YoY to ₹8,137.23 lakh and total income growing 39.44% YoY to ₹8,054.38 lakh. EBITDA increased 55.88% YoY to ₹429.23 lakh, expanding margins by 56 bps to 5.33%. PAT surged 450.33% YoY to ₹115.02 lakh with diluted EPS of ₹0.21. For H1 FY27, revenue reached ₹16,205.40 lakh (+27.68% YoY) and PAT stood at ₹244.76 lakh (+390.40% YoY). Growth was driven by operationalization of the Jadcherla OSD facility and expanding market reach across LATAM and Africa.

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements